Somatostatin receptor subtype gene expression in human and rodent tumors

https://doi.org/10.1016/0024-3205(93)90614-9Get rights and content

Abstract

Somatostatin (SRIF) analogues display anti-tumor properties believed to be mediated by specific cell surface somatostatin receptors (SSTR). SSTR subtypes have unique pharmacological properties, including specific GTP-binding protein coupling, ion channel regulation, and cAMP inhibition; therefoe, identification of isotypes expressed in tumor cells facilitates current efforts to design potent anti-tumor SRIF analogues. Human and rodent solid, transplantable tumors and tumor cell lines were examined for gene expression of SSTR1, SSTR2 and SSTR3 by reverse transcription of tumor mRNA and subsequent amplification of cDNA by the polymerase chain reaction, using SSTR subtype-specific oligonucleotide primers. SSTR2 mRNA transcripts were observed in all of the tumor cell lines examined. SSTR1 gene expression was seen in several human and rat types, and SSTR3 gene expression observed in two rodent tumor types. SSTR mRNA-positive tumors are expected to possess membrane-bound receptors which could potentially interact with anti-tumor SRIF analogues.

References (24)

  • J. Epelbaum

    Prog. Neurobiol.

    (1986)
  • J.E. Taylor et al.

    Biochem. Biophys. Res. Comm.

    (1988)
  • H.-L. Wang et al.

    Neurosci.

    (1990)
  • K. Yasuda et al.

    J. Biol. Chem.

    (1992)
  • M. Vanetti et al.

    FEBS

    (1992)
  • P. Brazeau et al.

    Science

    (1973)
  • S. Reichlin

    N. Engl. J. Med.

    (1983)
  • S. Reichlin

    J. Lab. Clin. Med.

    (1987)
  • A.V. Schally

    Cancer Res.

    (1988)
  • H. Parmer et al.

    Cancer Treat. Rev.

    (1989)
  • S.W.J. Lamberts et al.

    Endocrine Rev.

    (1991)
  • A.E. Bogden et al.

    Cancer Res.

    (1990)
  • Cited by (57)

    • A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice

      2001, European Journal of Cancer
      Citation Excerpt :

      The expression of SST receptors by non-SCLC remains controversial. While non-SCLC are described by many investigators as SST receptor- negative cancers [12,13,32,33], Eden and Taylor [34] detected mRNA for SST receptor subtype 2 in two non-SCLC cell lines. Adding to the complexity of the issue, Siegfried and colleagues [35] recently showed that under certain conditions, non-SCLC may acquire characteristics, such as the expression of gastrin releasing peptide (GRP), a hormone associated with the growth of various tumours including SCLC.

    View all citing articles on Scopus
    View full text